Florida Behavioral Medicine | Largo Clinic 1
Status and phase
Conditions
Treatments
About
This is a single-arm, open-label Phase 2 study to assess the safety, tolerability, pharmacokinetics (PK), and activity of ANC-501 oral capsules as adjunctive treatment in subjects diagnosed with major depressive disorder (MDD)
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Loading...
Central trial contact
Phil Perera, MD; Lara Dennie
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal